Abstract
The myelodysplastic/myeloproliferative neoplasms represent disorders, which at initial presentation, demonstrate overlapping features of myelodysplasia and myeloproliferation. Entities included in this group of neoplasms are chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, and myelodysplastic/ myeloproliferative neoplasm, unclassifiable (including refractory anemia with ring sideroblasts associated with marked thrombocytosis). This review discusses each of these entities separately, including their characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features, differential diagnoses, and therapeutic approaches (including targeted therapy).
Keywords: Chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, refractory anemia with ring sideroblasts associated with marked thrombocytosis
Current Cancer Therapy Reviews
Title: Myelodysplastic/Myeloproliferative Neoplasms
Volume: 8 Issue: 1
Author(s): Cherie H. Dunphy
Affiliation:
Keywords: Chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, refractory anemia with ring sideroblasts associated with marked thrombocytosis
Abstract: The myelodysplastic/myeloproliferative neoplasms represent disorders, which at initial presentation, demonstrate overlapping features of myelodysplasia and myeloproliferation. Entities included in this group of neoplasms are chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, and myelodysplastic/ myeloproliferative neoplasm, unclassifiable (including refractory anemia with ring sideroblasts associated with marked thrombocytosis). This review discusses each of these entities separately, including their characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features, differential diagnoses, and therapeutic approaches (including targeted therapy).
Export Options
About this article
Cite this article as:
H. Dunphy Cherie, Myelodysplastic/Myeloproliferative Neoplasms, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462530
| DOI https://dx.doi.org/10.2174/157339412799462530 |
Print ISSN 1573-3947 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
Current Status of Regulatory T Cells in Tumor Immune Escape and Immunotherapy
Regulatory T cells (Tregs) are a class of immunoregulatory suppressor cells characterized by the expression of CD4, CD25, and the transcription factor Forkhead box P3 (Foxp3). It plays an important role in maintaining immune homeostasis and inducing immune tolerance, and its dysfunction directly leads to the imbalance of immune homeostasis. ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Choroidal Neovascularization in High Myopia
Current Drug Targets Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Bile Acid Derivatives as Ligands of the Farnesoid X Receptor: Molecular Determinants for Bile Acid Binding and Receptor Modulation
Current Topics in Medicinal Chemistry Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Current Cardiology Reviews Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Lessons Learned from HIV Vaccine Clinical Efficacy Trials
Current HIV Research The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry mTOR, a Potential Target to Treat Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Orphan Nuclear Receptor Modulators
Current Topics in Medicinal Chemistry Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Vascular Calcification in Chronic Kidney Disease: Role of Disordered Mineral Metabolism
Current Pharmaceutical Design Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Design Potential Selective Inhibitors for Treating Cancer by Targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with Core Hopping Approach
Protein & Peptide Letters Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia
Current Drug Targets





